EFFICACY AND SAFETY OF LANSOPRAZOLE IN TREATMENT OF ZOLLINGER-ELLISON-SYNDROME. FIRST 6 MONTHS OF FOLLOW-UP

Objectives. - The aim of this prospective study was to confirm the eff icacy and safety of lansoprazole in patients with Zollinger-Ellison sy ndrome (ZES). Methods - Fourteen patients (5 W, 9 M) with ZES, age (me an +/- SD) 55.5 +/- 12.8 years, were included in the study. Study desi gn: initially and at 1, 3 and 6 months thereafter the following items were assessed: clinical signs, fasting serum gastrin (FSG), basal acid output (BAO) before next dose of lansoprazole. BAO <10 mmol H+/h was considered as efficient. Initially and at 6 months, laboratory tests ( hematology, liver, renal and hormonal), endoscopy and histological ent erochromaffin-like cell and gastrin cell density assessments were perf ormed. Lansoprazole initial dose was adjusted according to clinical sy mptoms and secretory studies. Results - At 6 months, lansoprazole dose s of 60, 90, 120 and 180 mg/d maintained BAO <10 mmol H+/h in 9, 2, 1 and 1 patient, respectively. No significant changes in FSG, endocrine cells densities and biological parameters were noted during treatment. Neither adverse events nor carcinoid tumors were observed. We conclud e that lansoprazole is efficient and well tolerated in patients with Z ES.